[3H]phenazine-3-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: [3H]phenazine-3-one
• 英文别名: phenazine-3-one；phenazin-3-one；10H-phenazin-2-one
• 化学式: C₁₂H₈N₂O
• 分子量: 196.208
• InChiKey: AZHUGLQVXUMICS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-羟基吩嗪 生成 [3H]phenazine-3-one
  参考文献：
  名称：

  Photochromism of Aza-aromatics with Hydroxy Group. Intermolecular Proton Transfer in Glassy Solution

  摘要：

  当2-羟基吩嗪（1）、3-羟基吖啶（2）和7-羟基喹啉（3）的溶液在77 K下用紫外线照射时，它们会变成深色。当这些溶液在77 K或更高温度下放置在黑暗中时，它们的颜色会恢复到原来的颜色。我们将光致变色归因于质子互变异构，这很可能是由激发态下的分子间质子转移引起的。

  DOI：

  10.1246/cl.2003.840

文献信息

• [EN] PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS<br/>[FR] DÉRIVÉS DE PHÉNAZINE-3-ONE ET DE PHÉNOTHIAZINE-3-ONE POUR LE TRAITEMENT DE TROUBLES DU STRESS OXYDATIF
  申请人：EDISON PHARMACEUTICALS INC

  公开号：WO2014145119A1

  公开（公告）日：2014-09-18

  Disclosed herein are phenazine-3-one and phenothiazine-3-one derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging.

  本文披露了苯并咪唑-3-酮和苯并噻唑-3-酮衍生物化合物以及使用这些化合物治疗或抑制氧化应激性疾病的方法，包括线粒体疾病、能量处理障碍、神经退行性疾病和衰老疾病。
• AGENT FOR IMPROVING MITOCHONDRIAL DYSFUNCTION, PREVENTATIVE OR THERAPEUTIC AGENT FOR DISEASES OR SYMPTOMS CAUSED BY MITOCHONDRIAL DYSFUNCTION, AND APPLICATIONS THEREFOR
  申请人：Jichi Medical University

  公开号：EP3708161A1

  公开（公告）日：2020-09-16

  An object of the present invention is to provide a means for substantially improving mitochondrial dysfunction. An aspect of the present invention relates to an agent for improving mitochondrial dysfunction, comprising a compound represented by the following formula, a stereoisomer or a salt thereof, or a solvate thereof, as an active ingredient. Another aspect of the present invention relates to a medicament or a pharmaceutical composition comprising the aforementioned compound, a stereoisomer or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, as an active ingredient, for use in preventing or treating a disease or symptom caused by mitochondrial dysfunction.

  本发明的目的是提供一种实质性改善线粒体功能障碍的方法。本发明的一个方面涉及一种改善线粒体功能障碍的制剂，该制剂包含下式所代表的化合物、其立体异构体或盐，或其溶解物作为活性成分。本发明的另一方面涉及一种药物或药物组合物，包含上述化合物、其立体异构体或其药学上可接受的盐，或其药学上可接受的溶液，作为活性成分，用于预防或治疗由线粒体功能障碍引起的疾病或症状。
• Agent for improving mitochondrial dysfunction, preventative or therapeutic agent for diseases or symptoms caused by mitochondrial dysfunction, and applications therefor
  申请人：JICHI MEDICAL UNIVERSITY

  公开号：US11369615B2

  公开（公告）日：2022-06-28

  A means for substantially improving mitochondrial dysfunction is provided. An aspect of the present invention relates to an agent for improving mitochondrial dysfunction, having a compound represented by the following formula, a stereoisomer or a salt thereof, or a solvate thereof, as an active ingredient. Another aspect of the present invention relates to a medicament or a pharmaceutical composition having the aforementioned compound, a stereoisomer or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, as an active ingredient, for use in preventing or treating a disease or symptom caused by mitochondrial dysfunction.

  本发明提供了一种实质性改善线粒体功能障碍的方法。 本发明的一个方面涉及一种改善线粒体功能障碍的制剂，其活性成分为下式所代表的化合物、其立体异构体或盐，或其溶液。 本发明的另一方面涉及一种具有上述化合物、其立体异构体或其药学上可接受的盐，或其药学上可接受的溶解物作为活性成分的药物或药物组合物，用于预防或治疗由线粒体功能障碍引起的疾病或症状。
• PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
  申请人：Edison Pharmaceuticals, Inc.

  公开号：EP2970151A1

  公开（公告）日：2016-01-20
• US20140275045A1
  申请人：——

  公开号：US20140275045A1

  公开（公告）日：2014-09-18